ClinicalTrials.gg
Not yet recruitingNCT07556445Updated Apr 30, 2026

Longitudinal Assessment of Lung Function and Respiratory Muscle Strength Following Training of the Inspiratory Muscles in Frail Older Adults (IMT-3)

An interventional study of Inspiratory Muscle Training and Sham Inspiratory Muscle Training in Frailty Syndrome, Geriatric Health and Respiratory Muscle Weakness, sponsored by Universidad Francisco de Vitoria. Not yet recruiting. Open to participants aged 80 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Universidad Francisco de Vitoria · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
80 Years and older
Sex
All
01

Study summary

This study aims to evaluate the effects of an 8-week inspiratory muscle training program on lung function and respiratory muscle strength in frail older adults aged 80 years and above. Frailty is associated with reduced physical capacity, declines in functional performance, impaired respiratory performance, and a higher risk of disability. Inspiratory muscle training is a simple, low-cost intervention that may improve breathing function, inspiratory muscle strength, and overall health in very old adults, but evidence in this age group remains limited. Participants will be randomly assigned to one of two groups: a high-load inspiratory muscle training group or a low-load sham training group. Both groups will use a threshold device and perform 30 breaths once per day, five days per week, for eight weeks. The experimental group will train with progressively increasing resistance (50% to 80% of maximal inspiratory pressure), while the sham group will use a minimal and non-progressive load (15% of maximal inspiratory pressure). All sessions will be supervised and monitored for safety. The main goal of the study is to determine whether inspiratory muscle training improves maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP) and lung function. These outcomes will allow the evaluation of the clinical relevance of improvements in respiratory muscle strength in this population.

Assessments will be performed before the intervention, immediately after the 8-week program, and again at one and three months after the end of the intervention to examine both immediate and short-term effects. This study may contribute valuable evidence regarding the safety, feasibility, and clinical benefits of inspiratory muscle training in frail very old adults, particularly its impact on respiratory muscle strength and lung function, supporting its potential implementation in rehabilitation and geriatric care.

02

Conditions studied

  • Frailty Syndrome
  • Geriatric Health
  • Respiratory Muscle Weakness
  • Age-Related Frailty

Browse trials for

Keywords

  • Inspiratory Muscle Training
  • Older Adults
  • Lung Function
  • Respiratory Muscle Strength
03

In context

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

This study's planned enrollment of 30 is below the median of 83 across 772 interventional studies indexed under Frailty.

Browse Frailty studies →

Lead sponsor

Universidad Francisco de Vitoria is the lead sponsor of 54 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
80 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 80 years or older.
  • Clinical diagnosis of frailty, defined by a Short Physical Performance
  • Battery (SPPB) score \< 9.
  • Ability to stand and walk with or without assistive devices.
  • Ability to understand and follow instructions for inspiratory muscle training.
  • Stable medical condition for at least 3 months prior to enrollment.
  • Capacity to provide or availability of a legal

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive impairment that prevents understanding the procedures.
  • Diagnosis of neuromuscular diseases affecting respiratory muscles (e.g., ALS, myopathies).
  • Severe or uncontrolled hypertension (≥180/110 mmHg).
  • Recent thoracic or abdominal surgery (\<3 months).
  • Severe musculoskeletal disorders limiting participation in training.
  • History of recurrent syncope, severe dizziness, or intolerance to respiratory maneuvers.
  • Any condition judged by the research team to compromise safety or participation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Inspiratory Muscle Training

    Inspiratory Muscle Training Participants perform an 8-week inspiratory muscle training program using a threshold device (PowerBreathe). Training consists of 30 inspirations, once daily, 5 days per week. The initial load is set at 50% of each participant's maximal inspiratory pressure (MIP) and is increased weekly by 5 cmH#O up to 80% of MIP. All sessions are supervised by healthcare professionals, with continuous monitoring of oxygen saturation and heart rateExperi

    Device: Inspiratory Muscle Training

  • Sham comparator
    Inspiratory Muscle Training (Sham)

    Inspiratory Muscle Training (Sham) Participants follow the same 8-week training schedule using the threshold device (PowerBreathe), but with a constant load of 15% of maximal inspiratory pressure (MIP) and no weekly progression. Training consists of 30 inspirations, once daily, 5 days per week. The procedure mimics the experimental intervention but provides minimal physiological stimulus. All sessions are supervised, with monitoring of oxygen saturation and heart rate

    Device: Sham Inspiratory Muscle Training

Interventions

  • DeviceInspiratory Muscle Training

    Inspiratory Muscle Training Participants perform 30 breaths once daily, 5 days per week for 8 weeks using a threshold inspiratory muscle training device. The load begins at 50% of maximal inspiratory pressure (MIP) and increases by 5 cmH#O weekly up to 80% of MIP. Sessions are supervised and oxygen saturation and heart rate are monitored.

  • DeviceSham Inspiratory Muscle Training

    Sham Inspiratory Muscle Training Participants use the same device and schedule as the experimental group (30 breaths once daily, 5 days per week for 8 weeks) but with a constant load of 15% of maximal inspiratory pressure (MIP), with no weekly progression. This mimics the procedure while providing minimal physiological stimulus. Supervision and monitoring are identical to the experimental arm.

06

What researchers measure

Primary outcomes

  1. Maximal Inspiratory Pressure (MIP)

    Maximal Inspiratory Pressure (MIP) will be measured using a calibrated handheld manometer following standardized respiratory assessment guidelines. Participants will be instructed to perform a maximal inspiratory effort from residual volume through the mouthpiece with their nose occluded. At least three maneuvers will be recorded, ensuring less than 10% variability between attempts. The highest reproducible value (cmH2O) will be used for analysis. This measure reflects global inspiratory muscle strength and is widely validated in older and frail populations.

    Time frame: Before-intervention; Immediately after intervention; 1-month after intervention; 3 months after intervention

  2. Maximal Expiratory Pressure (MEP)

    Maximal Expiratory Pressure (MEP) will be measured using a calibrated handheld manometer following standardized respiratory assessment guidelines. Participants will be instructed to perform a maximal expiratory effort from residual volume through the mouthpiece with their nose occluded. At least three maneuvers will be recorded, ensuring less than 10% variability between attempts. The highest reproducible value (cmH2O) will be used for analysis. This measure reflects global inspiratory muscle strength and is widely validated in older and frail populations.

    Time frame: Before-intervention; Immediately after intervention; 1-month after intervention; 3 months after intervention

  3. Forced Vital Capacity

    Forced Vital Capacity (FVC) is the maximum volume of air, expressed in milliliters, that the subject is able to inhale during a forced inspiration, which will be measured using spirometry.

    Time frame: Before-intervention; Immediately after intervention; 1-month after intervention; 3 months after intervention

  4. Forced Expiratory Volume in the First Second (FEV1)

    Forced Expiratory Volume in the First Second (FEV1) is the maximum volume of air exhaled in the first second, measured in milliliters, which provides information on lung elasticity and will be measured using spirometry.

    Time frame: Before-intervention; Immediately after intervention; 1-month after intervention; 3 months after intervention

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — At this time, it is unclear whether individual participant data (IPD) will be shared. Data sharing will depend on institutional policies, ethical approvals, participant privacy considerations, and the feasibility of preparing de-identified datasets. A final decision will be made once data collection and analysis are completed.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Sep 2026, 3 months later.

Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 3 months is below that.

Counting every sponsor, half of 519 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Apr 29, 2026
StartEst.
May 20, 2026
Primary completionEst.
Sep 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07556445
Lead sponsor
Universidad Francisco de Vitoria
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
May 20, 2026 (estimated)
Primary completion
Sep 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Apr 30, 2026

Study contacts

Michelle Matos Duarte, PhD
Contact
michelle.matos@ufv.es
+34 913 24 80 64

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion